FDA Inspection 1178720 — APEX Biologix, LLC

APEX Biologix, LLC — FEI 3013756523

The FDA completed an inspection of APEX Biologix, LLC on Sep 1, 2022 in Woods Cross, UT. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Biologics.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 1, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Woods Cross, UT (United States)

Citations

IDCFRDescription
1471321 CFR 820.198(a)Lack of or inadequate complaint procedures
1472221 CFR 820.40Procedures not adequately established or maintained

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.